Sandoz
ZIEXTENZO
Manufacturer:
Sandoz
Name:
ZIEXTENZO
HCPCS Code Descriptor:
Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
Category:
Q Code
HCPCS:
Q5120
NDC(s):
61314-0866-01
Primary Type:
Oncology Biosimilar Colony Stimulating Factor
Generic Status:
Single-Source
Route of Administration:
Subcutaneous
About:
ZIEXTENZO is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Sandoz and administered via the Subcutaneous route of administration. The Q Code: Q5120 is aligned to the drug ZIEXTENZO.
Ziextenzo (pegfilgrastim) is used to prevent the lack of certain white blood cells (neutrophils) in the body by aiding in the production of these white blood cells. This medication is manufactured by Sandoz and is biosimilar to the drug Neulasta (J2506). Ziextenzo was aligned to the HCPCS code Q5120 July 2020. Patient assistance programs for this medication can be found through the Sandoz One Source program.
Access Pricing and More By Registering
HCPCS Added Date:
7/1/20
HCPCS Effective Date:
4/1/23
HCPCS Short Description:
Inj pegfilgrastim-bmez 0.5mg
Billing and Coding Guide:
https://www.ziextenzo.com/sites/ziextenzo_com/files/2023-07/248799-1_ZARXIO_and_ZIEXTENZO_Product_and_Billing_Guide_populated_0.pdf
Patient Assistance:
https://ziextenzo.com/